FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897626749> ?p ?o ?g. }

• W2897626749 endingPage "4602" @default.
• W2897626749 startingPage "4591" @default.
• W2897626749 abstract "The role of biosimilars in value-based oncology care Kashyap B Patel,1 Luiz H Arantes Jr,2 Wing Yu Tang,3 Selwyn Fung4 1Carolina Blood and Cancer Care, Rock Hill, SC, USA; 2Biosimilars Global Medical Affairs, Pfizer Essential Health, Pfizer Inc. New York, NY, USA; 3Health Economics and Outcomes Research, Pfizer Health & Impact, Pfizer Essential Health, Pfizer Inc. New York, NY, USA; 4Pfizer Essential Health Research & Development, Pfizer Inc. New York, NY, USA Abstract: Biopharmaceuticals (biologics) represent one of the fastest growing sectors of cancer treatment. They are recommended for treating underlying cancer and as supportive care for management of treatment side effects. Given the high costs of cancer care and the need to balance health care provision and associated budgets, patient access and value are the subject of discussion and debate in the USA and globally. As the costs of biologics are high, biosimilars offer the potential of greater choice and value, increased patient access to treatment, and the potential for improved outcomes. Value-based care aims to improve the quality of care, while containing costs. The Centers for Medicare & Medicaid Services (CMS) has developed value-based care programs as alternatives to fee-for-service reimbursement, including in oncology, that reward health care providers with incentive payments for improving the quality of care they provide. It is anticipated that CMS payments in oncology care will be increasingly tied to measured performance. This review provides an overview of value-based care models in oncology with a focus on CMS programs and discusses the contribution of biosimilars to CMS value-based care objectives. Biosimilars may provide an important tool for providers participating in value-based care initiatives, resulting in cost savings and efficiencies in the delivery of high-value care through expanded use of biologic treatment and supportive care agents during episodes of cancer care. Keywords: biologics, biosimilars, oncology, patient access, value-based care, supportive care" @default.
• W2897626749 created "2018-10-26" @default.
• W2897626749 creator A5011943650 @default.
• W2897626749 creator A5026937562 @default.
• W2897626749 creator A5073038475 @default.
• W2897626749 creator A5082053760 @default.
• W2897626749 date "2018-10-01" @default.
• W2897626749 modified "2023-10-10" @default.
• W2897626749 title "The role of biosimilars in value-based oncology care" @default.
• W2897626749 cites W150730354 @default.
• W2897626749 cites W1968741068 @default.
• W2897626749 cites W1974756900 @default.
• W2897626749 cites W1989722114 @default.
• W2897626749 cites W2016637221 @default.
• W2897626749 cites W2025424758 @default.
• W2897626749 cites W2040533210 @default.
• W2897626749 cites W2050056063 @default.
• W2897626749 cites W2053883514 @default.
• W2897626749 cites W2060861099 @default.
• W2897626749 cites W2072300193 @default.
• W2897626749 cites W2080214410 @default.
• W2897626749 cites W2080261918 @default.
• W2897626749 cites W2100439220 @default.
• W2897626749 cites W2106100939 @default.
• W2897626749 cites W2109334536 @default.
• W2897626749 cites W2111285159 @default.
• W2897626749 cites W2124148088 @default.
• W2897626749 cites W2130011407 @default.
• W2897626749 cites W2130202488 @default.
• W2897626749 cites W2133042104 @default.
• W2897626749 cites W2133113022 @default.
• W2897626749 cites W2136919572 @default.
• W2897626749 cites W2139366207 @default.
• W2897626749 cites W2143743735 @default.
• W2897626749 cites W2146353390 @default.
• W2897626749 cites W2161097769 @default.
• W2897626749 cites W2289244316 @default.
• W2897626749 cites W2340007672 @default.
• W2897626749 cites W2411272761 @default.
• W2897626749 cites W2413636075 @default.
• W2897626749 cites W2465657364 @default.
• W2897626749 cites W2467939344 @default.
• W2897626749 cites W2470796247 @default.
• W2897626749 cites W2508040614 @default.
• W2897626749 cites W2529430742 @default.
• W2897626749 cites W2530856438 @default.
• W2897626749 cites W2545293585 @default.
• W2897626749 cites W2562706699 @default.
• W2897626749 cites W2574068890 @default.
• W2897626749 cites W2579032291 @default.
• W2897626749 cites W2590456758 @default.
• W2897626749 cites W2606245581 @default.
• W2897626749 cites W2610819809 @default.
• W2897626749 cites W2612700049 @default.
• W2897626749 cites W2613669325 @default.
• W2897626749 cites W2621291362 @default.
• W2897626749 cites W269470825 @default.
• W2897626749 cites W2737000731 @default.
• W2897626749 cites W2750998710 @default.
• W2897626749 cites W2769218683 @default.
• W2897626749 cites W2993089647 @default.
• W2897626749 doi "https://doi.org/10.2147/cmar.s164201" @default.
• W2897626749 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6199968" @default.
• W2897626749 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30410395" @default.
• W2897626749 hasPublicationYear "2018" @default.
• W2897626749 type Work @default.
• W2897626749 sameAs 2897626749 @default.
• W2897626749 citedByCount "25" @default.
• W2897626749 countsByYear W28976267492019 @default.
• W2897626749 countsByYear W28976267492020 @default.
• W2897626749 countsByYear W28976267492021 @default.
• W2897626749 countsByYear W28976267492022 @default.
• W2897626749 countsByYear W28976267492023 @default.
• W2897626749 crossrefType "journal-article" @default.
• W2897626749 hasAuthorship W2897626749A5011943650 @default.
• W2897626749 hasAuthorship W2897626749A5026937562 @default.
• W2897626749 hasAuthorship W2897626749A5073038475 @default.
• W2897626749 hasAuthorship W2897626749A5082053760 @default.
• W2897626749 hasBestOaLocation W28976267491 @default.
• W2897626749 hasConcept C10138342 @default.
• W2897626749 hasConcept C126322002 @default.
• W2897626749 hasConcept C144133560 @default.
• W2897626749 hasConcept C145097563 @default.
• W2897626749 hasConcept C160735492 @default.
• W2897626749 hasConcept C162324750 @default.
• W2897626749 hasConcept C175444787 @default.
• W2897626749 hasConcept C2776534028 @default.
• W2897626749 hasConcept C2779703844 @default.
• W2897626749 hasConcept C29122968 @default.
• W2897626749 hasConcept C50522688 @default.
• W2897626749 hasConcept C512399662 @default.
• W2897626749 hasConcept C59491497 @default.
• W2897626749 hasConcept C71924100 @default.
• W2897626749 hasConceptScore W2897626749C10138342 @default.
• W2897626749 hasConceptScore W2897626749C126322002 @default.
• W2897626749 hasConceptScore W2897626749C144133560 @default.
• W2897626749 hasConceptScore W2897626749C145097563 @default.
• W2897626749 hasConceptScore W2897626749C160735492 @default.

• next